News

Anne Winkler, MD, discusses her upcoming CCR East presentation, “Targeting Lupus Nephritis.”

At Pri-Med West, primary care providers ask Dr. Michael Ziffra and Dr. Shirah Vollmer all the questions they have about treating mental illness and prescribing different classes of drugs.

A new study suggests a close examination of the medical histories of patients with generalized pustular psoriasis can make clear which are most likely to die or be hospitalized in the ICU.

Adolescents with a GLP-1 RA prescription within year of T2D diagnosis were more probable to be in better glycemic control and less probable to be prescribed insulin.

The inflammatory markers and leukocyte profiles detailed in the study had not been previously evaluated in any longitudinal studies.

Significantly more patients treated with upadacitinib achieved clinical remission compared to patients treated with placebo.

In patients with T2D, adding Gla-300 to GLP-1 RA significantly improved glycemic control without significantly increasing hypoglycemia.

Despite this, an increased incidence of mild to moderate oral candidiasis was also observed in the pooled data from 8 trials.

While genetics are linked to gout diagnosis and lifestyle factors are related to risk, the association between healthy choices and risk mitigation remained unclear.

Dr. Shirah Vollmer and Dr. Michael Ziffra host a Question & Answer Session addressing common inquiries about mental health treatment in the primary care setting.

A continued discussion into misconceptions surrounding obesity treatments and how to better empower patients seeking out treatment.

Dr. Charles Vega suggestion doctors be less prescriptive in suggestion diets to patients.

Drugs like semaglutide are able to treat both diabetes and obesity.

A discussion into available pharmacotherapy for obesity and the uptake in practice of newer agents.

These findings suggest the importance of COVID-19 vaccination for patients with OHT.

The prevalence of sleep-disordered breathing differed across various etiologies of heart failure.

Dr. Michael Ziffra talked during Pri-Med West 2022 about some of the challenges and gaps in research needed for better bipolar disorder care.

There was no statistically significant difference in mean systolic blood pressure for the self-monitoring groups vs the usual care group.

Rheumatoid arthritis is known risk factor for cardiovascular disease, but how much do you know about the association? Test your knowledge with this quiz.

In the double blinded study, patients were randomized to receive anifrolumab (300mg monthly), an intensified regimen of 3 x 900mg doses followed by 300mg monthly, or standard of care therapy with mycophenolate mofetil and oral glucocorticoids.

Recent research has indicated that photos of skin can be used to assess AD severity.

Massachusetts General Hospital surgery resident Selena S. Li, MD, discusses her overseas volunteer work caring for refugees escaping their home during the Russia invasion.

Treating 100 older patients (≥60 years) with hypertension for approximately 3 years would prevent 1 major adverse cardiovascular event.

Sleep disordered breathing is frequently cited in patients with heart failure due to multiple factors included hypoxemia, sympathetic activation and systematic inflammation.

Investigators observed a potential risk between Black individuals with baseline signs of dehydration, SCT and related mortality over 30 years.

The study authors used data from Medicare beneficiaries who survived a heart attack between 1995 and 2019.

The daily oral combination therapy will be reconsidered for treating endometriosis pain this August.

Investigators believe that the BPDAI may under-estimate overall disease severity in darker skin types.

Investigators observed no reduction in readmission or mortality in a remote monitoring program with incentives for patients previously hospitalized for HF.

After years of frustration and failure, trials of targeted biologic therapy in systemic lupus erythematosus are beginning to show success. New drugs, including anifrolumab (Saphnelo) and belimumab (Benlysta), are paving the way for an exciting new era. However, this raises new questions as to how these novel therapeutics will be incorporated into future clinical practice.